文献速递胰腺与胆道疾病消化内镜

内镜逆行胰胆管造影术后胰腺炎的发生率、严重程度和死亡率:145项随机对照试验的系统综述和Meta分析更新

Incidence, severity, and mortality of post-ERCP pancreatitis: an updated systematic review and meta-analysis of 145 randomized controlled trials.
PubMed 文献 · Gastrointest Endosc · 2023-03-31

该研究基于MEDLINE、Embase和Cochrane数据库截至2022年6月的系统检索,纳入145项随机对照试验中安慰剂或无支架组的19038例患者,采用随机效应比例模型Meta分析。结果显示内镜逆行胰胆管造影术后胰腺炎总体累积发生率为10.2%(95%CI 9.3-11.3),高危患者为14.1%(95%CI 11.5-17.2);重症胰腺炎和死亡率分别为0.5%(95%CI 0.3-0.7)和0.2%(95%CI 0.08-0.3),高危患者重症为0.8%(95%CI 0.4-1.6)、死亡率为0.2%(95%CI 0-0.3)。1977年至2022年发生率趋势无统计学变化(P=0.48)。

要点

  • 内镜逆行胰胆管造影术后胰腺炎总体累积发生率为10.2%(95%CI 9.3-11.3)。
  • 高危患者内镜逆行胰胆管造影术后胰腺炎累积发生率为14.1%(95%CI 11.5-17.2)。
  • 重症内镜逆行胰胆管造影术后胰腺炎和死亡相对少见,死亡率0.2%(95%CI 0.08-0.3)。

核心结论

  • 基于145项随机对照试验安慰剂或无支架组的系统综述,内镜逆行胰胆管造影术后胰腺炎总体发生率为10.2%,高危患者为14.1%,1977年至2022年该发生率未见变化;重症胰腺炎和死亡相对少见。

研究设计与样本

  • 系统综述和Meta分析,检索MEDLINE、Embase和Cochrane数据库自建库至2022年6月的全文随机对照试验,评估内镜逆行胰胆管造影术后胰腺炎预防措施。
  • 纳入145项随机对照试验中安慰剂或无支架组的19038例患者,记录连续患者和高危患者的内镜逆行胰胆管造影术后胰腺炎发生率、严重程度和死亡率。
  • 采用随机效应比例模型Meta分析计算内镜逆行胰胆管造影术后胰腺炎发生率、严重程度和死亡率。

主要发现

  • 总体累积内镜逆行胰胆管造影术后胰腺炎发生率为10.2%(95%CI 9.3-11.3),主要来自开展此类随机对照试验的学术中心。
  • 在91项随机对照试验共14441例患者中,重症内镜逆行胰胆管造影术后胰腺炎累积发生率为0.5%(95%CI 0.3-0.7),死亡率为0.2%(95%CI 0.08-0.3)。
  • 在35项随机对照试验共3733例高危患者中,内镜逆行胰胆管造影术后胰腺炎累积发生率为14.1%(95%CI 11.5-17.2),重症为0.8%(95%CI 0.4-1.6),死亡率为0.2%(95%CI 0-0.3)。
  • 1977年至2022年随机分配至安慰剂或无支架组的患者中,内镜逆行胰胆管造影术后胰腺炎发生率总体趋势保持不变(P=0.48)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The incidence, severity, and mortality of post-ERCP pancreatitis (PEP) largely remain unknown with changing trends in ERCP use, indication, and techniques. We sought to determine the incidence, severity, and mortality of PEP in consecutive and high-risk patients based on a systemic review and meta-analysis of patients in placebo and no-stent arms of randomized control trials (RCTs). METHODS: The MEDLINE, Embase, and Cochrane databases were searched from the inception of each database to June 2022 to identify full-text RCTs evaluating PEP prophylaxes. The incidence, severity, and mortality of PEP from the placebo or no-stent arms of RCTs were recorded for consecutive and high-risk patients. A random-effects meta-analysis for a proportions model was used to calculate PEP incidence, severity, and mortality. RESULTS: One hundred forty-five RCTs were found with 19,038 patients in the placebo or no-stent arms. The overall cumulative incidence of PEP was 10.2% (95% confidence interval [CI], 9.3-11.3), predominantly among the academic centers conducting such RCTs. The cumulative incidences of severe PEP and mortality were .5% (95% CI, .3-.7) and .2% (95% CI, .08-.3), respectively, across 91 RCTs with 14,441 patients. The cumulative incidences of PEP and severe PEP were 14.1% (95% CI, 11.5-17.2) and .8% (95% CI, .4-1.6), respectively, with a mortality rate of .2% (95% CI, 0-.3) across 35 RCTs with 3733 patients at high risk of PEP. The overall trend for the incidence of PEP among patients randomized to placebo or no-stent arms of RCTs has remained unchanged from 1977 to 2022 (P = .48). CONCLUSIONS: The overall incidence of PEP is 10.2% but is 14.1% among high-risk patients based on this systematic review of placebo or no-stent arms of 145 RCTs; this rate has not changed between 1977 and 2022. Severe PEP and mortality from PEP are relatively uncommon.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Akshintala VS, Kanthasamy K, Bhullar FA, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: an updated systematic review and meta-analysis of 145 randomized controlled trials. Gastrointest Endosc. 2023. PMID: 37004815. doi:10.1016/j.gie.2023.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。